Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dexamethasone + dipyrone + hydroxocobalamin** is an injectable combination drug used primarily for the management of acute and chronic inflammatory and pain conditions, such as lumbar sciatic pain and acute joint inflammation. Dexamethasone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive effects, acting through glucocorticoid receptors to modulate gene expression and inflammatory mediator production. Dipyrone (also known as metamizole) is a non-opioid analgesic and antipyretic agent of the pyrazolone class, providing pain relief and reduction of fever through inhibition of prostaglandin synthesis, likely via cyclooxygenase enzymes. Hydroxocobalamin is a biologically active form of vitamin B12 with essential roles in cellular metabolism and neuroprotection, and it may further contribute to neural repair in nerve injury. The combination is under investigation in parenteral formulations for enhanced efficacy in acute inflammatory pain syndromes, particularly where rapid and multimodal analgesia is required[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + dipyrone + hydroxocobalamin.